Press release —
All patients treated in Sigrid Therapeutics' STAR clinical trial
Stockholm, July 16, 2019 - Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial. The project is on track and the results of the trial will be reported in October this year.
SiPore15 is a medical device, the first of its kind, that uses specially engineered mesoporous silica particles to lower blood sugar levels - both in prediabetics and newly diagnosed type 2 diabetics.
Sana Alajmovic, CEO and co-founder of Sigrid Therapeutics, comments: "It is very pleasing that the data collection in the STAR trial is on schedule and that, as already communicated, we will be able to report the results in October. No side effects have been reported so far, thus confirming the high safety and tolerability profile we have observed in previous clinical studies."
Details of the 24-week STAR (Sigrid Therapeutics HbA1c Reduction) trial, which involved 40 patients at two centers, one in Sweden and the other in Finland, can be found at www.clinicaltrials.gov/ct2/show/NCT03823027 and https://www.sigridthx.com .
Topics
Categories
SIGRID is a Swedish consumer health company developing technologies designed to reduce the metabolic impact of modern meals. The company’s patented SiPore® technology works locally in the gastrointestinal tract by interacting with digestive enzymes involved in carbohydrate and fat digestion. By slowing nutrient breakdown during digestion, SiPore® supports steadier post-meal metabolic responses. SIGRID collaborates with clinicians, researchers, and health innovators to translate metabolic science into practical solutions supporting metabolic health, weight management, and glucose stability. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
